This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: February 20th, 2009 - February 20th, 2010
This activity is no longer available for credit, however its content is still relevant for your educational needs.
This activity was developed for pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their knowledge concerning the implementation of a value-based benefit design for cancer care.
At the completion of this activity participants should be able to:
- Identify the intersection of epidemiologic shifts in the American cancer patient population, new cancer drug costs, and new diagnostic measures, on achieving value-based clinical treatment
- Recognize the role of value (cost, quality, access) in the new value-based healthcare system and the incentives of payers and purchasers to meet each of these 3 aspects of value in cancer care
- Discuss how NCCN clinical practice treatment guidelines are aiding all stakeholders in attaining value-based cancer care amidst rising new product costs
- Incorporate value-based principles in the treatment of cancer
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakersâ€™ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.
The associates of Medical Learning Institute, Inc. have no financial relationships to disclose. The associates of Center of Excellence Media, LLC, have no financial relationships to disclose.
Kavita Nair, PhD, is a consultant and researcher for Centocor and a researcher for Amgen, Novartis, and Daiichi Sankyo.
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.
Al Benson III, MD, FACP is a scientific advisor and has received research support from Amgen Inc., Bristol-Myers Squibb, Genentech, Inc., Imclone Systems Inc., MDS Nordion, Wyeth, Pfizer Inc., Roche Laboratories Inc., sanofi-aventis, and Taiho Pharmaceutical Co., Ltd.
*Content will include non-FDA-approved uses.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.